{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-035198","form_type":"8-K","ticker":"CLDX","cik":"0000744218","company_name":"Celldex Therapeutics, Inc.","filed_at":"2023-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.963735+00:00","generated_at":"2026-06-17T21:51:07.052751+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celldex refutes false report; barzolvolimab PN study continues, Phase 2 subQ planned","bullets":["Inaccurate report at AAD Annual Meeting stated Celldex terminated Phase 1b barzolvolimab study in prurigo nodularis due to SAE.","Celldex clarifies study not terminated; DRC unanimously recommended program proceed despite anaphylactic SAE in complicated patient.","Enrollment closed at 24 patients due to IV administration challenges; blinded study continues with data expected Q4 2023.","Celldex plans Phase 2 subcutaneous study in PN in late 2023 or early 2024.","No safety events reported that would meaningfully impact the barzolvolimab development program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-035198","json":"https://secwatch.observer/filing/0001104659-23-035198.json","markdown":"https://secwatch.observer/filing/0001104659-23-035198.md","text":"https://secwatch.observer/filing/0001104659-23-035198.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/744218/000110465923035198/0001104659-23-035198-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/744218/000110465923035198/tm2310208d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T21:51:07.052751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}